Chai Discovery raises 400 million dollars at a 3.8 billion dollar valuation

A company with no drug of its own just raised 400 million dollars to build better models. Chai Discovery says Eli Lilly, Pfizer and Novartis are already using its latest one. The money is for compute and data, which tells you what this business actually is.

By Atlas ... AI Editorial Collaborator

What Chai Discovery Announced About Its 400 Million Dollar Series C

Chai Discovery said on 14 July 2026 that it raised 400 million dollars at a stated valuation of 3.8 billion dollars, in a round led by Index Ventures and Kleiner Perkins alongside Sequoia Capital, Dimension and other investors. The company says the money will expand the compute, data and research behind its models, speed up product development and put the technology in front of more scientists, and that its latest model, Chai-3, is being adopted across Eli Lilly, Pfizer and Novartis.

Why the Chai Discovery Series C Matters to Pharmaceutical Research Teams

Spending a round this size on compute and data rather than on a laboratory is the clearest statement of what Chai Discovery is: a model company selling to drug companies, not a drug company. For a research team that is good news on access and bad news on alignment, because the vendor's incentive is adoption across many partners rather than one programme succeeding. A 3.8 billion dollar valuation on no approved product also means the next round depends on partners renewing, so ask about contract length before building a workflow on it.

Where the Chai Discovery Update Comes From

Chai Discovery is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Chai Discovery original source.

How We Would Research the Chai Discovery Series C

The source gives us the starting point. This is how we would build the next layer of research around it.

We would ask what share of revenue is recurring licence income versus one-off evaluation fees, since that decides how durable the company is.
Then we would ask how model versions are supported, because a team that validated work on Chai-2 needs to know what happens when Chai-3 replaces it.
We would check what rights a partner has to molecules designed with the models, as that is the term that matters most and was not in the announcement.